33. Puher SL, Berger AL, Bermudez MC et al. Correspondence and offprint requests to: Ming-Hui Zhao; E-mail: mhzhao@bjmu.edu.cn or Fu-de Zhou; E-mail: zhoufude1801@vip.sina.com A B S T R A C T Background. Rituximab had been shown to be effective in inducing remission of nephrotic syndrome in patients with idiopathic membranous nephropathy (iMN). This study applied rituximab therapy for 36 non-responsive iMN patients to investigate its effects and safety.
Results. Fifteen of the 36 (41.7%) patients achieved partial (n ¼ 13) or complete (n ¼ 2) response to the rituximab treatment. The median time for achieving partial response was 4.0 months (IQR 3.0-6.0). The responders had relatively lower levels (118 6 112 U/mL versus 345 6 357 U/mL, P ¼ 0. , P ¼ 0.02) with two patients reaching end-stage kidney disease. Two of the 15 patients relapsed during the follow-up period with anti-PLA2R antibody reoccurrence and B-cell reconstitution. The second course of rituximab combined with tacrolimus induced a faster partial response again in one patient. Conclusion. Rituximab therapy could induce remission of proteinuria and stabilization of renal function in non-responsive iMN patients, even those with damaged renal function. Anti-PLA2R antibodies may be used as a marker for individualized rituximab dosage and treatment monitoring.
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I N T R O D U C T I O N
Idiopathic membranous nephropathy (iMN) is the major pathological type of nephrotic syndrome of adult patients in China [1] . The prevalence of iMN has dramatically increased in recent years, especially in northern China [2] .
About one-third of iMN patients will undergo spontaneous remission within 1 year after onset [3] . For those with nephrotic syndrome, proteinuria of !4 g/day and estimated glomerular filtration rate (eGFR) !30 mL/min/1.73 m 2 , and who fail to respond to 6 months of treatment with antihypertensive and antiproteinuric agents, the 2012 Kidney Disease: Improving Global Outcome guidelines [4] recommend an initial immunosuppressive regimen that combines corticosteroids and an alkylating agent or calcineurin inhibitor as the first-line choice. Although it was thought that Asian people with iMN had a favorable prognosis, $5-14% of refractory patients progress to end-stage renal disease (ESRD) [5, 6] .
The identification of the main target podocyte antigen, phospholipase 2 receptor (PLA2R), provides a better understanding of the pathogenesis of iMN as an autoimmune entity [7] . B cells may play a pathogenic role in iMN as antigen-presenting cells or as autoantibody-producing cells. Rituximab, a chimeric monoclonal antibody, binding specifically to the CD20 receptor of cell membrane of precursor B cells and mature B cells, induces the depletion of B lymphocytes through apoptosis via antibody-dependent cellular cytotoxicity and complementdependent cytotoxicity. Since 2002, many studies had indicated that therapy with two to four doses of rituximab is likely to result in complete remission in 20-33% of patients and partial remission in 20-60% of patients who fail to respond to treatments with cyclophosphamide or calcineurin inhibitors [8] [9] [10] [11] . The depletion of B cells and the decline of anti-PLA2R antibodies anticipate the resolution of proteinuria [12] [13] [14] .
This was the first prospective study in Chinese iMN patients applying rituximab as a second-line therapy for those refractory patients who failed to respond to prior immunosuppressive regimens. The objective was to reveal the efficacy and safety of rituximab to non-responsive iMN and monitor the application of anti-PLA2R antibodies.
M A T E R I A L S A N D M E T H O D S

Patients
Since November 2013, Peking University First Hospital adopted a rituximab treatment for iMN patients fulfilling the following criteria: (i) biopsy-proven MN, (ii) non-responsive to initial therapy, defined as persistent nephrotic syndrome after 6 months and (iii) no secondary cause identified for MN. Patients who previously responded to immunomeds were eligible if they developed a nephrotic syndrome relapse that became non-responsive.
The research was approved by the ethics committee of Peking University First Hospital. Informed consent was obtained for sampling tissue and blood.
Rituximab treatment and follow-up
Rituximab (375 mg/m 2 ) was reconstituted in saline to a final concentration of 1 mg/mL and was infused at an initial rate of 40 mL/h, then progressively increased to 200 mL/h according to each patient's tolerability. Circulating B cells were monitored the next day after administration. B-cell depletion was defined as <5 B cells/mm 3 in the circulation. The number of rituximab injections, doses per injection and dosing interval were left to the discretion of the treating physicians.
Serial laboratory evaluations were performed to establish a baseline before rituximab administration, and were repeated on every visit in Months 1, 2, 3, 6, 9 and 12 and at subsequent 3-month intervals after rituximab administration.
At least a 6-month follow-up period was requested of all enrolled patients. Follow-up ended when the patients received other immunosuppressant or received dialysis.
Sample collection and anti-PLA2R antibodies detection
Plasma samples were collected on the day of rituximab therapy and on the day of each follow-up visit, and were stored in aliquots at À80 C until use. Circulating anti-PLA2R antibodies were detected using a commercial enzyme-linked immunosorbent assay (ELISA) kit (EUROIMMUN AG, Lübeck, Germany). In the procedure, patients' plasma was diluted 1:100 in PBST, then added to the reaction area on a microplate and incubated at room temperature for 30 min. After washing, the microplate was incubated with enzyme-conjugated secondary antibodies at room temperature for 30 min. Then the results were recorded as the net optical absorbance at 450 nm (Bio-Rad 550, Tokyo, Japan). Antibody positivity was defined as the level over 20 U/mL.
Treatment responses and renal outcomes
For evaluation of therapeutic responses, complete response was defined as urinary protein excretion <0.3 g/day. Partial response was defined as urinary protein excretion <3.5 g/day, and a !50% reduction from peak values, accompanied by improvement or a normalization of the serum albumin concentration, or stable serum creatinine with elevation <30% of baseline level. Patients who did not meet the definitions above were considered to be non-responders. Relapse was defined as recurrence of proteinuria !3.5 g/day after a period of partial or complete response.
For evaluation of kidney outcomes, the primary endpoint was ESRD.
Statistical analysis
Statistical analysis was performed using statistical software SPSS 13.0 (SPSS Inc., Chicago, IL, USA). Parametric data were presented as means 6 standard deviation (SD). Nonparametric data were presented as median [interquartile range (IQR)]. Inter-group differences with respect to quantitative parameters were assessed using a t-test for normally distributed data. Differences of semi-quantitative data were tested with the Kruskal-Wallis test or the Mann-Whitney U-test. Differences of qualitative data were compared using a 'chi-squared' test, Fisher's exact test or one-way analysis of variation (ANOVA). All probabilities were two-tailed and the level of significance was set at 0.05.
R E S U L T S Patients
From November 2013 to March 2016, 36 consecutive nonresponsive iMN patients were enrolled in the present study. Their demographic and clinical data are shown in Table 1 .
There were 6 female and 30 male patients, with an average age of 47.3 6 17.6 years. They had experienced a median of 45.1 months (IQR 5-132 months) of iMN history since their percutaneous renal biopsy operation. All the patients had been administered at least one course (mean 2.8 courses, range 1-5) of immunosuppressant therapy, including corticosteroid plus cyclophosphamide in 30 patients, cyclosporine in 30 patients, tacrolimus in 17 patients, mycophenolate mofetil in 12 patients, leflunomide in 3 patients and intravenous immunoglobulin in 6 patients. Twenty of the 36 patients achieved complete or partial remission during prior therapies. The other 16 patients never responded to any regimen.
By the time of enrollment, the average level of proteinuria was 12.3 6 5.9 g/24 h. Serum creatinine was 182.5 6 126.1 lmol/L. Renal function in four patients progressed rapidly due to a >30% increment of serum creatinine in the previous 3 months and their serum creatinine was 328 6 140 lmol/L. A repeated renal biopsy was conducted in two of the four patients just before rituximab infusion and the pathological results showed iMN with acute tubulointerstitial injury probably because of prior calcineurin administration. In the remaining 32 patients with stable renal function, the mean serum creatinine was 164 6 113 lmol/L. 
Rituximab regimen
Fifteen patients received the standard four-dose rituximab infusion and the total dose was 2173 6 457 mg per patient. The other 21 patients received the B-cell-oriented rituximab administration, with 3 patients receiving one dose of 500 6 173 mg per patient, 11 patients receiving two infusions for a total dose of 1099 6 118 mg per patient and 7 patients receiving three infusions for a total dose of 1500 6 173 mg per patient. B-cell depletion (<5 cells/mm 3 ) was achieved in all 36 patients.
Treatment responses
All the patients were followed up every 1-3 months for a median of 12.0 months (IQR 9.0-19.3). There were 15/36 (41.7%) patients who achieved complete (n ¼ 2, 5.6%) or partial response (n ¼ 13, 36.1%). The median time for achieving partial response was 4.0 months (IQR 3.0-6.0). Compared with the patients with no response, there were no differences in the baseline levels of proteinuria, serum albumin and renal function between the two groups ( Table 1) .
The total dose of rituximab was comparable between the responders and the non-responders (1606 6 529 mg versus 1552 6 731 mg, P ¼ 0.80). One in 3 (33.3%) patients, 3 in 11 (27.3%) patients, 5 in 7 (71.4%) patients and 6 in 15 (40%) patients receiving one, two, three and four doses, respectively, of rituximab achieved remission.
Anti-PLA2R antibodies were available in 34 patients and were positive in 32 (94.1%) patients before rituximab treatment. Two patients with negative anti-PLA2R antibody achieved partial response. In the 32 patients with anti-PLA2R antibodies, the antibody level was significantly lower in the 13 responders than the 19 non-responders (118 6 112 versus 345 6 357 U/mL, P ¼ 0.03). After the rituximab treatment, anti-PLA2R antibodies turned negative in all but one responder (declined from 74 to 36 U/mL), but the antibody level persisted positive in all non-responders (270 6 471 U/mL).
Of the 20 patients who achieved response with prior immunosuppressants, 11 (55.0%) achieved response after the rituximab treatment. The treatment response was better than the patients who never achieved remission by prior immunosuppressive drugs (4/16, 25.0%) (P ¼ 0.06).
Kidney outcomes
The patients who achieved response maintained a stable kidney function during the study period, with eGFR 53.3 6 40.5 mL/min/1.73 m 2 before rituximab treatment and 55.6 6 33.2 mL/min/1.73 m 2 at the end of follow-up (P ¼ 0.67). Of them, three patients with acute renal disease at enrollment responded well with eGFR increased from 19. (Table 2) . Two patients entered into dialysis at the 6th month after rituximab treatment.
Serial monitorings are shown in Figure 1 for antibody, proteinuria, serum albumin and creatinine after rituximab treatment in responders (n ¼ 9) and non-responders (n ¼ 13) who had been followed-up for 12 months.
Relapse
Two patients relapsed during follow-up (Supplementary data, Figure S1 ). One patient received a two-dose rituximab treatment, and the other received a four-dose treatment. Both achieved Bcell depletion and reduction in anti-PLA2R antibody titers with partial remission of proteinuria. After 2-3 months, anti-PLA2R antibody titers began to rise simultaneously with recurrence of proteinuria. One patient responded to a second course of rituximab in combination with tacrolimus.
Severe adverse effects
Rituximab was well tolerated in most patients. No severe adverse event was observed during infusions in all the patients. Only one patient suffered from soft tissue infection of lower extremity 1 month after the second dose of rituximab treatment. The infection was treated successfully with oral antibiotics and local antibiotics ointment.
D I S C U S S I O N
Our study showed that the rituximab treatment was effective in 41.7% of non-responsive iMN patients. Before these patients received the rituximab treatment, they had undergone an average of 45.1 months and had received an average of two to three courses of immunosuppressant therapies. Although the response rate in the current study was not so effective as previous reports that achieved an almost 65% remission rate [10, 15, 16] , rituximab treatment still appears to be a successful treatment choice for the non-responsive patients.
Several reasons could explain the difference in remission rate between the current study and previous trials. First, the enrolled patients in this study were all non-responsive iMN who might be more resistant to another immunosuppressive drug. Second, most patients in this study presented with damaged renal function with a mean level of serum creatinine >2 mg/dL. Previous studies have shown that patients with tubulointerstitial lesions and impaired renal function respond worse than those with normal renal function. The KDOQI guideline also does not recommend patients with serum creatinine >3 mg/dL to receive immunosuppressant therapy [4] . In the present study, rituximab still produced a better response in some of the patients with damaged acute or chronic renal function. Third, the dosage level of rituximab may be not enough for some patients in this study. The issue of optimal dosage of rituximab in iMN treatments is still a matter of debate. Rituximab doses varied significantly in different studies, ranging from a single dose of 375 to four doses of 375 mg/m 2 . The four-dose regimen was adopted from the treatment for Hodgkin's lymphoma [17] . However, the load of CD20 cells is much lower in patients with iMN than in those with lymphoproliferative diseases. Subsequently, to induce a complete B-cell depletion might require a much smaller dose of rituximab. A prospective matched-cohort study suggested a B-cell-driven rituximab treatment approach [12] . B-cell depletion defined as <5 B cell/mm 3 of peripheral blood was designed as the goal of optimal dosage of rituximab [12] . This B-celldriven protocol was associated with similar efficacy to the four-dose regimen, but with fewer adverse events and significant cost-saving. However, a recent study with low-dose rituximab to obtain B-cell depletion showed only 44% of patients achieving remission in 12 months after the rituximab treatment [18] . As in this study, B-cell depletion was very easy to achieve with lowdose rituximab but depletion alone perhaps may not be an effective means to determine the optimal dose of rituximab.
Results of this study showed that the responders had lower levels of anti-PLA2R antibodies, and that antibody depletion or reduction was achieved in all the patients in 1-3 months after the rituximab infusion. Among the non-responders, the reduction of antibody level was not significant or was followed by reelevation of antibody levels, although they all achieved B-cell depletion. These results implied that the anti-PLA2R antibody level may be a promising marker for the decisions concerning rituximab dosage and monitoring the treatment responses. The rituximab dosage should be individualized according to the level of anti-PLA2R antibodies. Previous reports in the literature also showed that anti-PLA2R antibody was sensitive and specific for iMN, and the reduction or disappearance of the antibody within 3-12 months after rituximab infusion was correlated with a better response to treatment [13] [14] [15] . Ruggenenti et al. [13] analyzed 132 iMN patients treated with rituximab, monitoring the 24-h proteinuria and anti-PLA2R antibodies. The lower baseline antibody titer and complete antibody depletion 6 months after the treatment were found to be the best predictors of disease remission [13] . A multicenter, randomized controlled trial also suggested that anti-PLA2R antibodies could be an early marker of rituximab treatment [15] . This study evaluated the remission rate between the patients who received non-immunosuppressive antiproteinuric treatment (NIAT) and those who received rituximab and NIAT. At 6 months, there was no significant difference between the two groups according to the remission rate (21.1% versus 35.5%, P ¼ 0.21), while anti-PLA2R antibody depletion was obtained in the NIAT-rituximab group (56% versus 4.3%, P < 0.001).
In the two relapsed patients, the reduction and then resumption of antibody titer were followed by the change of proteinuria accordingly. Compared with B cells, the anti-PLA2R antibody seemed to be a better response marker of proteinuria. The results emphasized that the anti-PLA2R antibody should be closely monitored even after antibody depletion. Re-elevation of the antibody count implied the possibility of pending relapse. Timely extra infusion of rituximab perhaps could avoid the resurgence of proteinuria.
Clearly, rituximab monotherapy was effective in inducing remission in patients with iMN. However, achieving remission appears to be time dependent. As in a recent GEMRITUX study, the response rate was 35.1% at 6 months and 64.9% at 12 months after rituximab infusion, and of which, the complete remission rate constituted a relatively low number (18.9%) [15] . Similarly, in a report of 100 patients with iMN who received rituximab monotherapy, complete remission occurred in 27% of patients and partial remission in 38% of patients and nearly 30% of the remission patients relapsed [10] .
In one of the two relapsed patients of this study who was retreated with rituximab accompanied with tacrolimus, the procedure of remission was accelerated compared with the first course of rituximab monotherapy. Similar efficacy was also seen in patients of this study who received rituximab along with tacrolimus as the first-line regimen although this was not shown in the present study. Moroni et al. [19] reported a combination therapy of rituximab with cyclosporine in 13 patients of iMN: rituximab plus cyclosporine for 6 months as induction therapy and a second cycle of rituximab with a gradual reduction of cyclosporine as the maintenance phase. This method resulted in faster and higher rate of remission. Ninety-two percent of patients achieved partial or complete remission by 6 months and 54% achieved complete remission.
The major limitations of this study were the relatively small sample size, limited duration of follow-up and non-uniformity of treatment protocols. However, the results clearly showed that anti-PLA2R antibody-oriented treatment strategy, not uniformity of protocol, should be preferred in the design of future studies.
In conclusion, rituximab therapy may induce remission of proteinuria and stabilization of renal function in nonresponsive iMN patients with a high risk of progression of renal dysfunction. Anti-PLA2R antibodies may be used as a marker to optimize the rituximab usage.
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